Evaluation of Ameliorative Potentials of Cleanshield Liquid Supplement in Testosterone Induced Benign Prostatic Hyperplastic (BPH) Rat Model

Main Article Content

O. C. Ozoana
U. A. Obisike


Aim: The aim of this study was to evaluate the ameliorative effect of Cleanshield Liquid Supplement in Testosterone Induced Benign Prostatic Hyperplasic (BPH) in male albino rats

Study Design:  This study is a case controlled experimental study.

Place and Duration of Study: Department of Medical Laboratory Science, Rivers State University, Port Harcourt, Nigeria, between December, 2019 and May, 2020.

Methodology: A total of 30 male albino wistar rats were used for this study and divided into 6 groups of 5 rats each. Testosterone propionate (4 mg/kg) was used to induced BPH subcutaneously in the rats and then were given (0.5 mg/kg) dutasteride, an anti-BPH drug and Cleanshield liquid supplement (0.24ml, 0.48ml and 0.72ml) for 30 days. At the end of the 30 days treatment, the animals were sacrificed. Chloroform was used to anaesthetize the rats and 5 ml of whole blood samples were collected through cardiac puncture at the end of 8 hours fast. The blood samples collected were separated and the serum was used to analyze for prostate specific antigen (PSA) using rat specific PSA ELISA kit produced by Shanghai Korain Biotech Co., Ltd, China, while liver enzymes (alanine aminotransaminase (ALT), aspartate aminotransaminase (AST) and alkaline phosphatase (ALP)) were analyzed using spectrophotometric method. Liver tissues of the rats were excised and used for histological analysis. SPSS version 22.0 was used for statistical analysis and p<0.05 was considered statistically significant.

Results: The results showed that comparison between the Cleanshield treated groups and the Avodart group (group 3) showed no significant difference but there was a non-significant reduction in the mean PSA values of all the clean shield treated group with the group that received the highest amount of Cleanshield having the most reduced mean PSA value. The mean PSA value of the negative control group (NC) compared to dutasteride group and all Cleanshield group showed statistically significant difference. The mean ALT values did not show any significant difference statistically when the groups that received Cleanshield supplement were compared to PC group. In the mean values of AST, only the comparison between anti BPH group and the group that received 0.72ml of Cleanshield produce statistically significant difference (p=0.036). That of the ALP comparison between the mean ALP values of the PC group (grp 2) showed significant difference against group 2(p=0.001) and against group 5 (p=0.003). Avodart group (group 3) showed a statistical difference when compared to group 4(0.24 ml of Cleanshield) at p=0.000. Group 4(0.24 ml of Cleanshield) showed statistical difference when compared to group 5(0.48ml of Cleanshield) at p=0.001.

Conclusion: Conclusively, Cleanshield liquid supplement is not toxic to the liver but does not possess significant BPH ameliorative potentials.

Ameliorative potentials cleanshield liquid supplement, testosterone, Benign Prostatic Hyperplastic (BPH), rat.

Article Details

How to Cite
Ozoana, O. C., & Obisike, U. A. (2020). Evaluation of Ameliorative Potentials of Cleanshield Liquid Supplement in Testosterone Induced Benign Prostatic Hyperplastic (BPH) Rat Model. International Research Journal of Oncology, 3(4), 24-34. Retrieved from https://journalirjo.com/index.php/IRJO/article/view/30140
Original Research Article


McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Eng J Med. 1998;338:557-63.

Nimeh T, Magnan B, Almallah YZ. Benign prostatic hyperplasia: review of modern minimally invasive surgical treatments. Sem Interv Rad. 2016;33 (3):244-50.

Marberger M, Horkaway R, Rasette JD. Optimizing the medical management of benign prostatic hyperplasia. J Uro. 2004;45:411-19.

Mobley D, Feibus A, Baum N. Benign prostatic hyperplasia and urinary symptoms: evaluation and treatment. Postg Med J. 2015;127:301-307.

Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Uro Clin N Am. 2016;43:279-88.

Seftel AD, Rosen RC, Rosenberg T, Sadovsky T. Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: Practice patterns according to physician specialty. Int’l J Clin Pract. 2008;62(4): 614-22.

Ojewola RW, Oridota ES, Baloguna OS, Alabi TO, Ajayi AI, Olajide TA, Tijani KH, Jeje EA, Ogunjimi MA, Ogundare EO. Prevalence of Clinical Benign prostatic hyperplasia amongst community-dwelling men in a South-Western Nigerian rural setting: A cross-sectional study. Afr J Uro, 2017;23:109-15.

Keeth DW, Andriole GL. Medical therapy for benign proststic hyperplasia. J Adv Clin Med. 2002;164:11-15.

Lam JS, Cooper LK, Kaplan SA. Changing aspects in the evaluation and Treatment of patients with benign prostatic hyperplasia. J Med Clin N Am. 2004;88:281-308.

Grand View Research Dietary Supplements Market. Available online.

Tamgadge S, Tamgadge A, Agre Bhagyvashree. Internal pH in health and disease. Int’l J Curr Res. 2016;8(7):34315 - 20.

National Institute of Health. Guide for the Care and Use of Laboratory Animals prepared by the National Institute of Health; 1985.

Center for Drug Evaluation and Research. U.S. Department of Health and Human Services Food and Drug Administration: Conversion of Human and Animal doses for chemical used for pre-clinical studies; 2005.

Obisike UA, Boisa N, Nwachuku EO, Nduka N. Determination of exogenous testosterone propionate dose for induction of benign prostatic hyperplasiaiin rat model. Eur J Biomed Pharm Sci. 2019;6(13):141-7.

McCarthy U, Distaburd RT, Larry DG. Novel estimation of plasma protein. J Diag Med. 1983;232:241-45.

European Commission on Clinical Laboratory Standards. Determination of the catalytic activity concentration in serum of L-alanine aminotransferase (EC, ALAT). Klin Chem Mitt. 1989;20:204-11.

Bergmeyer HU, Horder M, Rej R. Approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part3. IFCC methodfor alanine aminotransferase. J Clin Chem Clin Biochem. 1986;24(7): 481-95.

Klein B, Read PA, Babson LA. Alkaline phospatase activity measurement. Clin Chem. 1960;6:269–75.

König D, Muser K, Dickhuth H, Berg A. Effect of a supplement rich in alkaline minerals on acid-base balance in humans. Nutr J. 2009;8(1):23–4.

Frasseto L, Barnerjee T, Powe N, Sebastian A. Acid balance, dietary acid load, and bone effects—A controversial subject. Nutrients. 2018;10(4):517–8.

Kapur S. A Medical Hypothesis: phosphorus balance and prostate cancer. Can Inv. 2000;18(7):664–9.

Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M. The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Ass J, 2009;3(2):109-14.

Talib WH, Mahasneh A. Antiproliferative activity of plant extracts used against cancer in traditional medicine. Sci Pharm, 2010;78(1):33–45.

Alberto B, Umberto C, Nazareno S, Andrea G, Andrea S, Marco B. Benign prostatic hyperplasia and its aetiologies. Eur Urol Supp. 2009;8:865–71.

Bañez L, Loftis R, Freedland S, Presti J, Aronson W, Amling C, Kane C, Terris M. The Influence of Hepatic Function on Prostate Cancer Outcomes Following Radical Prostatectomy. Prost Can Prost Dis, 2010;13(2):173–7.

Obisike UA, Boisa N, Nwachuku EO, Nduka N. Antiproliferative potentials of Zingiber Officinale in testosterone induced prostate hyperplastic albino wister rats. Int’l Res J Onco. 2020;3(2):20-30.

Fontana RJ. Severe acute hepatitis attributed to the herbal and dietary supplement OxyELITE pro. Clin Liv Dis, 2019;14(2):45–8.